The RSI Indicator for MBX moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 8 similar instances when the indicator left oversold territory. In 8 of the 8 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 23 of 27 cases where MBX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for MBX just turned positive on October 21, 2026. Looking at past instances where MBX's MACD turned positive, the stock continued to rise in 15 of 15 cases over the following month. The odds of a continued upward trend are 90%.
Following a +2.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where MBX advanced for three days, in 120 of 130 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
MBX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on September 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MBX as a result. In 26 of 29 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
MBX moved below its 50-day moving average on September 18, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MBX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for MBX entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.342) is normal, around the industry mean (2.988). P/E Ratio (-22.755) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. MBX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MBX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Aroon Indicator for NAMS entered a downward trend on October 14, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 166 similar instances where the Aroon Indicator formed such a pattern. In 143 of the 166 cases the stock moved lower. This puts the odds of a downward move at 86%.
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NAMS as a result. In 58 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 60%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NAMS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NAMS's RSI Oscillator exited the oversold zone, 25 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 60 cases where NAMS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
The Moving Average Convergence Divergence (MACD) for NAMS just turned positive on October 20, 2026. Looking at past instances where NAMS's MACD turned positive, the stock continued to rise in 42 of 59 cases over the following month. The odds of a continued upward trend are 71%.
Following a +8.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where NAMS advanced for three days, in 199 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
NAMS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.068) is normal, around the industry mean (2.988). P/E Ratio (-9.949) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (357.143) is also within normal values, averaging (438.009).
The Tickeron Profit vs. Risk Rating rating for this company is 66 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. NAMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
| MBX | NAMS | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 85% | 2 days ago 73% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 60% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 71% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 66% |
| TrendMonth ODDS (%) | 2 days ago 86% | 2 days ago 71% |
| Advances ODDS (%) | 2 days ago 90% | 3 days ago 81% |
| Declines ODDS (%) | 9 days ago 86% | 9 days ago 78% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 77% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 86% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MBX’s FA Score shows that 1 FA rating(s) are green while NAMS’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MBX’s TA Score shows that 5 TA indicator(s) are bullish while NAMS’s TA Score has 5 bullish TA indicator(s).
MBX (@Biotechnology) experienced а +10.47% price change this week, while NAMS (@Biotechnology) price change was +7.40% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
MBX is expected to report earnings on Nov 05, 2026.
NAMS is expected to report earnings on Nov 04, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, MBX has been loosely correlated with NAMS. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if MBX jumps, then NAMS could also see price increases.
| Ticker / NAME | Correlation To MBX | 1D Price Change % | ||
|---|---|---|---|---|
| MBX | 100% | +0.80% | ||
| NAMS - MBX | 40% Loosely correlated | -0.05% | ||
| IMVT - MBX | 40% Loosely correlated | -0.73% | ||
| PVLA - MBX | 38% Loosely correlated | +2.15% | ||
| SYRE - MBX | 38% Loosely correlated | +1.70% | ||
| SVRA - MBX | 38% Loosely correlated | -1.89% | ||
More | ||||
A.I.dvisor indicates that over the last year, NAMS has been loosely correlated with IMVT. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if NAMS jumps, then IMVT could also see price increases.
| Ticker / NAME | Correlation To NAMS | 1D Price Change % | ||
|---|---|---|---|---|
| NAMS | 100% | -0.05% | ||
| IMVT - NAMS | 45% Loosely correlated | -0.73% | ||
| VKTX - NAMS | 45% Loosely correlated | -1.24% | ||
| PTCT - NAMS | 43% Loosely correlated | -0.48% | ||
| KURA - NAMS | 42% Loosely correlated | -1.00% | ||
| RAPP - NAMS | 41% Loosely correlated | -14.67% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BPRO | 19.80 | 0.17 | +0.87% |
| Bitwise Proficio Currency Debasement ETF (BPRO) | |||
| EDOW | 46.56 | 0.20 | +0.43% |
| First Trust Dow 30 Equal Weight ETF (EDOW) | |||
| PMBS | 46.69 | N/A | N/A |
| PIMCO Mortgage-Backed Securities Active Exchange-Traded Fund (PMBS) | |||
| JAPN | 24.25 | N/A | N/A |
| Horizon Kinetics Japan Owner Operator ETF | |||
| MHIP | 21.31 | -0.03 | -0.12% |
| Milliman Healthcare Inflation Plus ETF (MHIP) | |||